NCT00759291 is a Phase 2, PHASE3 clinical trial of acipimox in Metabolic Syndrome, sponsored by Brigham and Women's Hospital.

Who is sponsoring NCT00759291?

NCT00759291 is sponsored by Brigham and Women's Hospital.

What drugs are being tested in NCT00759291?

Interventions in NCT00759291: acipimox, Placebo.

What condition does NCT00759291 study?

NCT00759291 studies Metabolic Syndrome.

Is NCT00759291 still recruiting?

NCT00759291 is currently completed. Last updated 21 February 2023.

Are results published for NCT00759291?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-02-21 · How we verify

NCT00759291

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome

Completed Phase 2, PHASE3 Results posted Last updated 21 February 2023

What this trial tests

Phase 2, PHASE3 trial testing acipimox in Metabolic Syndrome in 40 participants. Completed in 30 December 2017.

Timeline

1 April 2006

Primary endpoint
1 December 2017

30 December 2017

Quick facts

Lead sponsor	Brigham and Women's Hospital
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	basic science
Enrollment	40
Start date	1 April 2006
Primary completion	1 December 2017
Estimated completion	30 December 2017
Sites	1 location across United States

Drugs / interventions tested

acipimox (ACIPIMOX) — full drug profile →
Placebo

Conditions studied

Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

Brigham and Women's Hospital

Who can join

18 and older, any sex, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Flow Mediated Vasodilation Primary · After 7 days of each treatment.

Brachial artery response to a 5 minute blood pressure cuff-applied ischemic period

Placebo

Group	Value	95% CI
Metabolic Syndrome	9.5	± 6.5
Control	10.8	± 4.9

Acipimox

Group	Value	95% CI
Metabolic Syndrome	10.5	± 6
Control	10.9	± 6.2

Sponsor's own description

This study will test the hypothesis that reducing the release of free fatty acids (FFA) from fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with the metabolic syndrome.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Role of Serum Free Fatty Acids in Endothelium-Dependent Microvascular Function.
Sullivan AE, Courvan MCS, Ada AW, Wasserman DH, et al · · 2025 · PMID 39888728 · DOI 10.1002/edm2.70031

Verify or expand the search:

Other recruiting trials for Metabolic Syndrome

Currently open trials in the same condition.

NCT07501858 — Assessing the Association Between H. Pylori Persistence and the Severity of Insulin Resistance in Patients With Metaboli · recruiting
NCT06857929 — "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" · NA · recruiting
NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00759291 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 21 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00759291.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing